clinical trial · NCT04296903
Post-approval Registry Study to Evaluate the Continued Safety and Probable Benefit of the MID-C System for 5 Years Post-Implantation in Adolescent Idiopathic Scoliosis (AIS)
Apifix·N/A·active not recruiting·n = 201
Adolescent Idiopathic ScoliosisMID-C System
brief summary
The ApiFix MID-C System is a unidirectional expandable rod, designed to be connected unilaterally to the spine via 2 anchor points on the concave side of a scoliotic deformity above and below the apex of the major curvature to treat adolescent idiopathic scoliosis. The MID-C System is designed to act as an internal brace. Patients implanted with the device in the US within 2 years of FDA's approval of H17001 should be enrolled in the study. A minimum number of 200 patients will be enrolled in this study.
started
May 31, 2020
primary completion
Jun 30, 2029
completion
Jun 30, 2030
last updated
Oct 3, 2025
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol